4.84
Urogen Pharma Ltd Aktie (URGN) Neueste Nachrichten
Deadline Approaching: UroGen Pharma Ltd. (URGN) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith - Business Wire
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Desi - GuruFocus
UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer - Business Wire
UroGen presents promising bladder cancer study results - Investing.com Australia
UroGen presents promising bladder cancer study results By Investing.com - Investing.com Canada
UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Lost Money on UroGen Pharma Ltd. (URGN)? Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - PR Newswire
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - StreetInsider
Securities Lawsuit Alert: UroGen Pharma Ltd. (URGN) InvestorsContact Levi & Korsinsky Before July 28, 2025 - ACCESS Newswire
Class Action Lawsuit Filed: UroGen Pharma Ltd. (URGN)Join by July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
URGN CLASS ACTION NOTICE: UroGen Pharma Ltd. has been Sued - GlobeNewswire
Levi & Korsinsky Investigates UroGen Pharma Ltd. (URGN) Over Possible Securities Fraud - ACCESS Newswire
Pharma Co. Hid Cancer Study Method Problems, Investor Claims - Law360
URGN ALERT: Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of UroGen Pharma Ltd. Investors - Business Wire
URGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
URGN Investor Notice: Robbins LLP Reminds Stockholders of the Class Action Lawsuit Against ... - Eagle-Tribune
Investigation Opened on Behalf of UroGen Pharma Ltd. (URGN) ShareholdersContact Levi & Korsinsky - ACCESS Newswire
Ongoing Securities Investigation into UroGen Pharma Ltd. (URGN)Contact Levi & Korsinsky - ACCESS Newswire
URGN FRAUD ALERT: UroGen Pharma Ltd. Investors are Alerted to Contact BFA Law about the Pending Securities Fraud Class Action - Newsfile
URGN STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire
URGN BREAKING NEWS: UroGen Pharma Ltd. Stock Plummets 45% Triggering Shareholder Class Action – Contact BFA Law if You Lost Money (NASDAQ:URGN) - Business Wire
UroGen Investor Sues After Cancer Therapy Setback, 45% Selloff - Bloomberg Law News
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against UroGen Pharma Ltd. (URGN) - GlobeNewswire Inc.
INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of - GlobeNewswire
URGN Investors Have the Opportunity to Lead the UroGen Pharma Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - PR Newswire
UroGen Pharma Ltd. (NASDAQ:URGN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
URGN Stockholder Alert: Robbins LLP Informs Investors of the UroGen Pharma Ltd. Class Action Lawsuit - Morningstar
UroGen Pharma Ltd. Investors: Please contact the Portnoy - GlobeNewswire
URGN INVESTOR ALERT: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen - Business Wire
Law Offices of Howard G. Smith Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action - Business Wire
UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Did You Suffer Losses in UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky About Securities Fraud Claims - ACCESS Newswire
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA's ODAC Vote Against UGN-102, Company Facing Investor ScrutinyHagens Berman - PR Newswire
Did UroGen Pharma Ltd. (URGN) Mislead Investors? Levi & Korsinsky Investigates - ACCESS Newswire
Oppenheimer maintains Outperform on UroGen Pharma stock By Investing.com - Investing.com India
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
UroGen Pharma to Present at TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA - New Castle News
UroGen Pharma Ltd. (URGN) Shares Crash Again Amid FDA’s - GlobeNewswire
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Position Decreased by Millennium Management LLC - Defense World
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Janus Henderson Group PLC Acquires New Stake in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Lazard Asset Management LLC Acquires New Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Q2 EPS Estimates for UroGen Pharma Raised by HC Wainwright - Defense World
UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug - Benzinga
Guggenheim Has Lowered Expectations for UroGen Pharma (NASDAQ:URGN) Stock Price - Defense World
The Goldman Sachs Group Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $3.00 - Defense World
Ongoing Investigation: UroGen Pharma Ltd. (URGN) May Have Misled ShareholdersLevi & Korsinsky Investigates - ACCESS Newswire
Northern Trust Corp Purchases 23,345 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World
Kaplan Fox Reminds Investors of UroGen Pharma Ltd. (URGN) to an Investigation of Potential Securities Law Violations - FinancialContent
Guggenheim's Michael Schmidt Lowers Price Target for UroGen Pharma (URGN) | URGN Stock News - GuruFocus
Kaplan Fox is Investigating Potential Securities Law Violations against UroGen Pharma Ltd. (URGN) - FinancialContent
UroGen Pharma (URGN) Price Target Cut by Guggenheim | URGN Stock News - GuruFocus
URGN ACTIVE INVESTIGATION: Lost Money on UroGen Pharma Ltd.? Contact Levi & Korsinsky Now - ACCESS Newswire
UroGen crashes as FDA AdCom rebukes bladder cancer drug - MSN
UroGen Pharma Shares Fall After HC Wainwright Downgrade - marketscreener.com
Kaplan Fox Announces an Investigation Into UroGen Pharma Ltd. (URGN) for Potential Securities Law Violations - FinancialContent
UroGen Pharma (URGN) Target Price Slashed by Goldman Sachs | URGN Stock News - GuruFocus
Goldman Sachs cuts UroGen Pharma target to $3 from $16 - Investing.com Australia
UroGen tanks as FDA panel vote goes against UGN-102 - The Pharma Letter
This Guidewire Software Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
HC Wainwright Downgrades UroGen Pharma to Neutral From Buy - marketscreener.com
UroGen Pharma (URGN) Downgraded by HC Wainwright & Co. | URGN Stock News - GuruFocus
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):